Limits...
Quantitative analysis of the association between CRP rs2808630 and rs1417938 polymorphisms and cancer risk.

Wang JG, Zhang Y, Xiao TL - Oncol Lett (2014)

Bottom Line: A search of the relevant literature was conducted using the PubMed database to identify eligible studies published up until March 25, 2014.Five case-control studies involving 888 cases and 3,167 controls for the 3407 A>G polymorphism, and six case-control studies involving 3,110 cases and 5,951 controls for the 29 A>T polymorphism were included in the current meta-analysis.The pooled odds ratios with 95% confidence intervals were calculated using the fixed- or random-effects model.

View Article: PubMed Central - PubMed

Affiliation: Department of Cancer Biotherapy, Cancer Institute, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China.

ABSTRACT

Accumulating evidence indicates that polymorphisms in the CRP gene are important in the development of cancer. The current meta-analysis was performed to investigate the association between CRP polymorphisms 3407 A>G (rs2808630) and 29 A>T (rs1417938), and the risk of developing cancer. A search of the relevant literature was conducted using the PubMed database to identify eligible studies published up until March 25, 2014. Five case-control studies involving 888 cases and 3,167 controls for the 3407 A>G polymorphism, and six case-control studies involving 3,110 cases and 5,951 controls for the 29 A>T polymorphism were included in the current meta-analysis. The pooled odds ratios with 95% confidence intervals were calculated using the fixed- or random-effects model. Meta-analysis identified no association between the CRP 3407 A>G and 29 A>T polymorphisms, and overall cancer risk. Additional stratified analysis by cancer type did not reveal any significant associations in the genetic models investigated. The findings of the present study indicated that CRP 3407 A>G and 29 A>T polymorphisms are not associated with cancer risk.

No MeSH data available.


Related in: MedlinePlus

Forest plot describing the meta-analysis using the recessive model to determine the association between the CRP (A) 3407 A>G (GG vs. GA+AA) and (B) 29 A>T (TT vs. TA+AA) polymorphisms and the risk of developing cancer. ID, identification; OR, odds ratio; CI, confidence interval.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4301552&req=5

f2-ol-09-02-0994: Forest plot describing the meta-analysis using the recessive model to determine the association between the CRP (A) 3407 A>G (GG vs. GA+AA) and (B) 29 A>T (TT vs. TA+AA) polymorphisms and the risk of developing cancer. ID, identification; OR, odds ratio; CI, confidence interval.

Mentions: Evaluation of the association between CRP 3407 A>G and 29 A>T polymorphisms and cancer risk are indicated in Fig. 2 and Table II. Overall, when all of the eligible studies were pooled, no significant associations were observed between the CRP 3407 A>G polymorphism and overall cancer risk [GG vs. GA+AA, (OR, 0.86; 95% CI, 0.62–1.19; Ph=0.81); GG+GA vs. AA, (OR, 1.09; 95% CI, 0.93–1.28; Ph=0.61); GG vs. AA, (OR, 0.91; 95% CI, 0.65–1.27; Ph=0.71); GA vs. AA, (OR, 1.13; 95% CI, 0.95–1.34; Ph=0.66); and G vs. A, (OR, 1.03; 95% CI, 0.90–1.17; Ph=0.63)] or the 29 A>T polymorphism and overall cancer risk [TT vs. TA+AA, (OR, 1.07; 95% CI, 0.97–1.18; Ph=0.60; TA+TT vs. AA, OR, 1.03; 95% CI, 0.90–1.17; Ph=0.74); TT vs. AA, (OR, 1.11; 95% CI, 0.94–1.31; Ph=0.49); TA vs. AA, (OR. 1.00; 95% CI, 0.87–1.15; Ph=0.86); and T vs. A, (OR, 1.04; 95% CI, 0.97–1.12; Ph=0.64)]. In the subgroup analysis by cancer type, the results also indicated that CRP 3407 A>G and 29 A>T polymorphisms were not associated with prostate, lung and colorectal cancer.


Quantitative analysis of the association between CRP rs2808630 and rs1417938 polymorphisms and cancer risk.

Wang JG, Zhang Y, Xiao TL - Oncol Lett (2014)

Forest plot describing the meta-analysis using the recessive model to determine the association between the CRP (A) 3407 A>G (GG vs. GA+AA) and (B) 29 A>T (TT vs. TA+AA) polymorphisms and the risk of developing cancer. ID, identification; OR, odds ratio; CI, confidence interval.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4301552&req=5

f2-ol-09-02-0994: Forest plot describing the meta-analysis using the recessive model to determine the association between the CRP (A) 3407 A>G (GG vs. GA+AA) and (B) 29 A>T (TT vs. TA+AA) polymorphisms and the risk of developing cancer. ID, identification; OR, odds ratio; CI, confidence interval.
Mentions: Evaluation of the association between CRP 3407 A>G and 29 A>T polymorphisms and cancer risk are indicated in Fig. 2 and Table II. Overall, when all of the eligible studies were pooled, no significant associations were observed between the CRP 3407 A>G polymorphism and overall cancer risk [GG vs. GA+AA, (OR, 0.86; 95% CI, 0.62–1.19; Ph=0.81); GG+GA vs. AA, (OR, 1.09; 95% CI, 0.93–1.28; Ph=0.61); GG vs. AA, (OR, 0.91; 95% CI, 0.65–1.27; Ph=0.71); GA vs. AA, (OR, 1.13; 95% CI, 0.95–1.34; Ph=0.66); and G vs. A, (OR, 1.03; 95% CI, 0.90–1.17; Ph=0.63)] or the 29 A>T polymorphism and overall cancer risk [TT vs. TA+AA, (OR, 1.07; 95% CI, 0.97–1.18; Ph=0.60; TA+TT vs. AA, OR, 1.03; 95% CI, 0.90–1.17; Ph=0.74); TT vs. AA, (OR, 1.11; 95% CI, 0.94–1.31; Ph=0.49); TA vs. AA, (OR. 1.00; 95% CI, 0.87–1.15; Ph=0.86); and T vs. A, (OR, 1.04; 95% CI, 0.97–1.12; Ph=0.64)]. In the subgroup analysis by cancer type, the results also indicated that CRP 3407 A>G and 29 A>T polymorphisms were not associated with prostate, lung and colorectal cancer.

Bottom Line: A search of the relevant literature was conducted using the PubMed database to identify eligible studies published up until March 25, 2014.Five case-control studies involving 888 cases and 3,167 controls for the 3407 A>G polymorphism, and six case-control studies involving 3,110 cases and 5,951 controls for the 29 A>T polymorphism were included in the current meta-analysis.The pooled odds ratios with 95% confidence intervals were calculated using the fixed- or random-effects model.

View Article: PubMed Central - PubMed

Affiliation: Department of Cancer Biotherapy, Cancer Institute, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China.

ABSTRACT

Accumulating evidence indicates that polymorphisms in the CRP gene are important in the development of cancer. The current meta-analysis was performed to investigate the association between CRP polymorphisms 3407 A>G (rs2808630) and 29 A>T (rs1417938), and the risk of developing cancer. A search of the relevant literature was conducted using the PubMed database to identify eligible studies published up until March 25, 2014. Five case-control studies involving 888 cases and 3,167 controls for the 3407 A>G polymorphism, and six case-control studies involving 3,110 cases and 5,951 controls for the 29 A>T polymorphism were included in the current meta-analysis. The pooled odds ratios with 95% confidence intervals were calculated using the fixed- or random-effects model. Meta-analysis identified no association between the CRP 3407 A>G and 29 A>T polymorphisms, and overall cancer risk. Additional stratified analysis by cancer type did not reveal any significant associations in the genetic models investigated. The findings of the present study indicated that CRP 3407 A>G and 29 A>T polymorphisms are not associated with cancer risk.

No MeSH data available.


Related in: MedlinePlus